Clinical trials
Systemic Sclerosis (SSc) clinical trials
Below are recruiting systemic sclerosis (ssc) clinical trials, each written for real people, not researchers. We’re tracking 99 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06675344Recruiting
A device for fatigue, Raynaud's, and quality of life in scleroderma
This trial tests if a device called Apollo can help reduce fatigue and Raynaud's symptoms and improve quality of life in people with scleroderma (systemic sclerosis). You would use the device at home and track your symptoms using a smartphone app.
New Orleans, LouisianaAges 18 years+ - NCT06658483Enrolling by invitation
Hand Scleroderma Experience Survey for People With Systemic Sclerosis
This study is testing a new scale to measure what it's like to live with hand problems caused by systemic sclerosis (scleroderma). By answering questions about your daily hand function, you can help doctors better understand your experience and improve care.
Malatya, MalatyaAges 18 years+ - NCT06658470Enrolling by invitation
Hand disability in scleroderma with digital ulcers
This study looks at hand function and disability in people with systemic sclerosis who have digital ulcers. It aims to understand how these ulcers affect daily hand use.
Denizli, MalatyaAges 18 years+ - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Phoenix, ArizonaAges 18 years+ - NCT06642870Recruiting
Self-management programme for rare rheumatic conditions
This trial is developing a self-management programme for people with rare rheumatic conditions like lupus, vasculitis, myositis, or Sjogren syndrome. It aims to help participants better manage their condition and improve their quality of life.
BristolAges 18 years+ - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06058091RecruitingPhase 1/Phase 2
Cell injection therapy for systemic sclerosis
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Nanjing, JiangsuAges 18–65 - NCT05989763Recruiting
Constipation study for people with systemic sclerosis
This study looks at why people with systemic sclerosis (a disease that can affect connective tissues) develop constipation. It will use special tests to measure how well the colon moves waste, and it may help doctors find better treatments.
Houston, TexasAges 18 years+ - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT04789850RecruitingPhase 2
Itacitinib for adults with diffuse systemic sclerosis
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
AmiensAges 18 years+ - NCT04356287RecruitingPhase 1/Phase 2
Cord cell treatment for severe systemic sclerosis symptoms
This early-phase study tests whether umbilical cord-derived “cord blood–type” cells can reduce or improve severe systemic sclerosis (a type of hardening/scarring disease of connective tissue). It may help people whose current standard treatments haven’t worked or caused side effects.
Montreal, QuebecAges 18 years+ - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT03211793RecruitingPhase 1/Phase 2
Cell treatment for painful hand sores in systemic sclerosis
This trial tests a cell-based treatment (mesenchymal stromal cells) to help heal painful finger/toe ulcers in people with systemic sclerosis. It is for ulcers that did not improve after a specific IV medicine called prostacyclins.
UtrechtAges 18 years+ - NCT07473154RecruitingPhase 1/Phase 2
Calming an overactive immune system with special cells
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
DüsseldorfAges 18 years+ - NCT07800871RecruitingPhase 1/Phase 2
FT839 cell therapy for autoimmune diseases
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
Fullerton, CaliforniaAges 18–70 - NCT07641634RecruitingPhase 1/Phase 2
Testing PRO-203 for active systemic sclerosis
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
Melbourne, VictoriaAges 18–65 - NCT07842133Recruiting
Relaxation exercises for fatigue and breathing in scleroderma
This study tests whether progressive muscle relaxation exercises can help reduce fatigue and shortness of breath while improving lung function in people with scleroderma. Participants will learn and practice these exercises as part of the study.
Gaziantep, ŞehitkamilAges 18–65 - NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Birmingham, AlabamaAges 18 years+ - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis (ssc)?
- Yes. Clin2 currently lists 99 recruiting systemic sclerosis (ssc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis (ssc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis (ssc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.